Powder: -20°C for 3 years | In solvent: -80°C for 1 year
IRAK4-IN-21 is a selective, orally active, potent IRAK4 inhibitor that acts on IRAK4 (IC50: 5 nM) and TAK1 (IC50: 56 nM). IRAK4-IN-21 exhibits potent inhibition of IL-23 production with an IC50 value of 0.17 μM. can be used to study autoimmune diseases, such as plaque psoriasis and psoriatic arthritis.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 301,000 |
50 mg | 約6-8 週間 | ¥ 392,500 |
100 mg | 約6-8 週間 | ¥ 594,500 |
説明 | IRAK4-IN-21 is a selective, orally active, potent IRAK4 inhibitor that acts on IRAK4 (IC50: 5 nM) and TAK1 (IC50: 56 nM). IRAK4-IN-21 exhibits potent inhibition of IL-23 production with an IC50 value of 0.17 μM. can be used to study autoimmune diseases, such as plaque psoriasis and psoriatic arthritis. |
分子量 | 513.57 |
分子式 | C28H28FN7O2 |
CAS No. | 2170694-04-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
IRAK4-IN-21 2170694-04-7 Inhibitor inhibitor inhibit